Evidence map›Paper›PMID 31998834›Full record

ArticleScience advances2020

Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer.

Kuan-Wei Huang, Fu-Fei Hsu, Jiantai Timothy Qiu, Guann-Jen Chern, Yi-An Lee, Chih-Chun Chang, Yu-Ting Huang, Yun-Chieh Sung, Cheng-Chin Chiang, Rui-Lin Huang and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
127citing papers in PubMed, 2 pooled it
12.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

127 citing papers in PubMed, 2 syntheses or guidelines pooled it, 252 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

67 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 1 country.

Kuan-Wei HuangInstitute of Biomedical Engineering and Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, Hsinchu 30013, Taiwan.ORCID 0000-0002-1937-645X
Fu-Fei HsuInstitute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.ORCID 0000-0002-2378-5854
Jiantai Timothy QiuCollege of Medicine, Chang Gung University, Taoyuan, Taiwan.ORCID 0000-0001-9294-3003
Guann-Jen ChernInstitute of Biomedical Engineering and Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, Hsinchu 30013, Taiwan.
Yi-An LeeInstitute of Biomedical Engineering and Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, Hsinchu 30013, Taiwan.
Chih-Chun ChangInstitute of Biomedical Engineering and Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, Hsinchu 30013, Taiwan.
Yu-Ting HuangInstitute of Biomedical Engineering and Nanomedicine, National Health Research Institutes, Miaoli County 35053, Taiwan.ORCID 0000-0002-1778-0205
Yun-Chieh SungInstitute of Biomedical Engineering and Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, Hsinchu 30013, Taiwan.
Cheng-Chin ChiangInstitute of Biomedical Engineering and Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, Hsinchu 30013, Taiwan.
Rui-Lin HuangInstitute of Biomedical Engineering and Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, Hsinchu 30013, Taiwan.
Chu-Chi LinDepartment of Biomedical Sciences, School of Medicine, Chang Gung University, Taoyuan, Taiwan.ORCID 0000-0001-9017-5004
Trinh Kieu DinhInstitute of Biomedical Engineering and Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, Hsinchu 30013, Taiwan.
Hsi-Chien HuangInstitute of Biomedical Engineering and Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, Hsinchu 30013, Taiwan.
Yu-Chuan ShihInstitute of Biomedical Engineering and Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, Hsinchu 30013, Taiwan.
Donia AlsonDepartment of Biomedical Sciences, School of Medicine, Chang Gung University, Taoyuan, Taiwan.ORCID 0000-0001-5033-3696
Chun-Yen LinCollege of Medicine, Chang Gung University, Taoyuan, Taiwan.ORCID 0000-0003-3007-3190
Yung-Chang LinDivision of Medical Oncology/Hematology, Chang Gung Memorial Hospital, Taoyuan, Taiwan.ORCID 0000-0002-2084-5348
Po-Chiao ChangDivision of Hepatology, Department of Gastroenterology and Hepatology, Linkou Medical Center; Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Shu-Yi LinInstitute of Biomedical Engineering and Nanomedicine, National Health Research Institutes, Miaoli County 35053, Taiwan.ORCID 0000-0002-6871-6617
Yunching ChenInstitute of Biomedical Engineering and Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, Hsinchu 30013, Taiwan.ORCID 0000-0001-6228-5169
National Tsing Hua University · TWChang Gung University · TWChang Gung Memorial Hospital · TWNational Health Research Institutes · TWInstitute of Biomedical Sciences, Academia Sinica · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While immunotherapy holds great promise for combating cancer, the limited efficacy due to an immunosuppressive tumor microenvironment and systemic toxicity hinder the broader application of cancer immunotherapy. Here, we report a combinatorial immunotherapy approach that uses a highly efficient and tumor-selective gene carrier to improve anticancer efficacy and circumvent the systemic toxicity. In this study, we engineered tumor-targeted lipid-dendrimer-calcium-phosphate (TT-LDCP) nanoparticles (NPs) with thymine-functionalized dendrimers that exhibit not only enhanced gene delivery capacity but also immune adjuvant properties by activating the stimulator of interferon genes (STING)-cGAS pathway. TT-LDCP NPs delivered siRNA against immune checkpoint ligand PD-L1 and immunostimulatory IL-2-encoding plasmid DNA to hepatocellular carcinoma (HCC), increased tumoral infiltration and activation of CD8

Indexed as

Biomarkers, TumorImmunogenetic PhenomenaMolecular Targeted TherapyNanoparticlesTheranostic NanomedicineAnimalsAntineoplastic Agents, ImmunologicalBiomarkersCalcium PhosphatesCytokinesDendritic CellsDrug Delivery SystemsGenetic TherapyGene Transfer TechniquesHumansImmunotherapyAntineoplastic Agents, ImmunologicalBiomarkersBiomarkers, Tumorcalcium phosphateCalcium PhosphatesCytokinesLipidsMembrane ProteinsRNA, Small InterferingSting1 protein, mouseSTING Protein

Identifiers

PMID31998834
PMCPMC6962042
OpenAlexW3000567428

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.